OtoImmune is bringing precision immunology into the mainstream, using multi-omic data and AI to catch chronic inflammatory conditions earlier, build a complete picture of each patient's biology, and drive better treatment decisions.
We start with autoimmunity.
Chronic, systemic and different in every patient, autoimmune disease is slow to diagnose and costly to treat. Care remains reactive, fragmented and largely trial-and-error.
830M
people affected globally
(est. 10%).
80%
of autoimmune patients are women.
5 years
across multiple specialists and clinics.
$180B
per year in the US alone.
Oncology point solutions work because a tumour is a fixed, biopsied target: a single genomic snapshot can guide treatment.
Autoimmunity has no equivalent. The immune system is dynamic and systemic, so effective care needs longitudinal, multi-layered data, not a single diagnostic test.

Turning patient engagement into discovery.
mOI connects patients, clinicians, health data and biological samples, using AI to uncover patterns over time and build the evidence needed to advance precision immunology.
Free membership driving patient acquisition and scale
Consented longitudinal data powering real-world evidence
Linked biobank enabling biomarker discovery
Engaged patient cohorts accelerating trials and partnerships
For clinicians, mOI Clinical (in development) brings specialists and their patients onto one shared record for continuous, data-driven care.




Whether you invest, partner or simply share our belief in precision immunology, we'd love to hear from you. Send us a message and the team will be in touch.